Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

lung adenocarcinoma cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Antibiotic (2) Apoptosis (7) Bacterial (3) c-Met/HGFR (1) Caspase (1) CDK (1) CTLA-4 (1) DNA/RNA Synthesis (1) Endogenous Metabolite (2) FAP (1) Histone Methyltransferase (1) Interleukin Related (1) MAP4K (1) NADPH Oxidase (1) PARP (2) PD-1/PD-L1 (3) PDGFR (1) Phosphodiesterase (PDE) (1) Pyruvate Kinase (1) Ras (1) Reactive Oxygen Species (ROS) (2) Transmembrane Glycoprotein (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (29) Infection (2) Inflammation/Immunology (4)

By Targets:

Adrenergic Receptor (1)

Antibiotic (2)

Apoptosis (7)

Bacterial (3)

c-Met/HGFR (1)

Caspase (1)

CDK (1)

CTLA-4 (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (2)

FAP (1)

Histone Methyltransferase (1)

Interleukin Related (1)

MAP4K (1)

NADPH Oxidase (1)

PARP (2)

PD-1/PD-L1 (3)

PDGFR (1)

Phosphodiesterase (PDE) (1)

Pyruvate Kinase (1)

Ras (1)

Reactive Oxygen Species (ROS) (2)

Transmembrane Glycoprotein (1)

VEGFR (1)

Wnt (1)

By Research Areas:

Cancer (29)

Infection (2)

Inflammation/Immunology (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147030

PARP1-IN-8	PARP	Cancer
PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated PARP1 inhibitor, with an IC₅₀ of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549 .

HY-147027

PARP-1-IN-2	PARP Caspase Apoptosis	Cancer
PARP-1-IN-2 (compound 11g) is a potent and BBB-penetrated PARP1 inhibitor, with an IC₅₀ of 149 nM. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .

HY-114356

BPI-9016M	c-Met/HGFR	Cancer
BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma .

HY-P99379

Nidanilimab (Nadunolimab) CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-P10944

Unlabeled FXX489 NNS309	FAP	Cancer
Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .

HY-164713

PARP1-IN-31	Others	Others
PARP1-IN-31 (compound 11f) is a phthalazinone-based compound, an anti-lung adenocarcinoma compound with inhibitory activity against PARP-1 (IC₅₀ value of 97 nM), inducing apoptosis and inhibiting cell proliferation in lung cancer cell lines.

HY-165245

SBI-183	Transmembrane Glycoprotein	Cancer
SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .

HY-148260

KRAS G12D inhibitor 16	Ras	Cancer
KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC₅₀ value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .

HY-138098

Sartorypyrone B	Endogenous Metabolite	Cancer
Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI₅₀s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases .

HY-N1056

Yunnancoronarin A Zerumbetol	Others	Cancer
Yunnancoronarin A (Zerumbetol) can be isolated from Hedychium forrestii. Yunnancoronarin A is cytotoxic, with IC₅₀ values of 11.08 and 2.19 μM against lung adenocarcinoma cells A549 and leukemia cells K562, respectively .

HY-N14303

16-Methyloxazolomycin	Antibiotic Bacterial	Infection Cancer
16-Methyloxazolomycin is an antibiotic. 16-Methyloxazolomycin has the effect of resisting bacteria and algae. 16-Methyloxazolomycin against leukemia P388 and human lung adenocarcinoma cells .

HY-N10363

Pixinol	Others	Cancer
Pixinol, a natural glycoside, shows cytotoxicity against the human lung carcinoma GLC4 and adenocarcinoma COLO 320 cell lines (IC₅₀=71 µM and 43 µM, respectively) .

HY-111320

Chrysomycin B	Bacterial Antibiotic	Cancer
Chrysomycin B is an antibiotic isolated from a strain of Streptomyces. Chrysomycin B causes DNA damage in the human lung adenocarcinoma A549 cell line and inhibits topoisomerase II. Chrysomycin B suppresses the growth of transplantable tumors in mice.

HY-144361

Antitumor agent-44	Apoptosis	Cancer
Antitumor agent-44 (Compound 5n) disrupts the mitochondrial homeostasis, induces cell cycle arrest and apoptosis in human adenocarcinoma cells. Antitumor agent-44 (Compound 5n) possesses good anti-tumor activity in a lung-cancer-cell xenograft mice model .

HY-172881

PKM2-IN-10	Pyruvate Kinase	Cancer
PKM2-IN-10 (Compound 16) is a PKM2 inhibitor. PKM2-IN-10 inhibits the proliferation of A549 and HCC1833 cell lines with IC₅₀ of 3.36 μM and 9.20 μM, respectively. PKM2-IN-10 exhibits antitumor activity in human non-small cell lung cancer (NSCLC) and mouse lung adenocarcinoma models. PKM2-IN-10 can be used in lung cancer research .

HY-174271

Antioxidant agent-21	Apoptosis	Cancer
Antioxidant agent-21 (Compound 9) is a phenolic heterocyclic compound with antioxidant and anticancer activities. Antioxidant agent-21 shows significant cytotoxicity toward human gastric adenocarcinoma (AGS) and lung cancer (A549) cells. Antioxidant agent-21 induces caspase-dependent apoptosis in cancer cells .

HY-N6005

Methyl caffeate	Bacterial	Infection Cancer
Methyl caffeate, an antimicrobial agent, shows moderate antimicrobial and prominent antimycobacterial activities. Methyl caffeate also exhibits α-glucosidase inhibition activity, oxidative stress inhibiting activity, anti-platelet activity, antiproliferative activity in cervix adenocarcinoma and anticancer activity in lung and leukmia cell lines .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-124745

KY-05009 1 Publications Verification	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .

HY-151295

Antitumor agent-75	DNA/RNA Synthesis	Cancer
Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC₅₀ value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer .

HY-P99048A

Sintilimab (Anti-PD-1) IBI308 (Anti-PD-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-159803

IST-622 6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin	Endogenous Metabolite	Cancer
IST-622 (6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin) is an anti-tumor agent with significant growth inhibitory activity. IST-622 exhibits significant anti-tumor effects against a variety of mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum cell sarcoma. IST-622 was orally administered and the results showed efficacy in different tumor types. In addition, IST-622 provided significant inhibitory effects against two human tumor xenograft models: large cell lung carcinoma (Lu-116) and gastric adenocarcinoma (St-4). IST-622 also exhibited significant growth inhibitory activity against P388 leukemia in vitro, with a half inhibitory concentration (IC50) more than 20 times lower than CT .

HY-N6969A

Dicentrine hydrochloride	Adrenergic Receptor	Cancer
Dicentrine hydrochloride is a drug with anti-inflammatory and anti-cancer activity. Dicentrine hydrochloride exerts its effects by enhancing TNF-α-induced apoptosis in A549 lung adenocarcinoma cells. Dicentrine hydrochloride increases caspase-8, -9, -3 and poly(ADP-ribose) polymerase (PARP) activities. Dicentrine hydrochloride inhibits TNF-α-induced invasion and migration of A549 cells. Dicentrine hydrochloride significantly inhibited the TNF-α-activated TAK1, p38, JNK and Akt signaling pathways, and reduced the transcriptional activities of NF-κB and AP-1 .

HY-147328

LCS3	Apoptosis	Cancer
LCS3 is a reversible and uncompetitive glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) inhibitor (IC₅₀=3.3 µM and 3.8 µM, respectively). LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research .

HY-156694

Hydroxy-PP-Me	Apoptosis NADPH Oxidase Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
Hydroxy-PP-Me is a selective CBR1 inhibitor with an IC₅₀ of 759 nM. Hydroxy-PP-Me can inhibit serum starvation-induced apoptosis. Hydroxy-PP-Me can enhance the cytotoxic effects of Daunorubicin (HY-13062A) and As₂O₃ on tumor cells. Hydroxy-PP-Me can be used in the research of cancer such as leukemia .

HY-P99117

Cadonilimab 1 Publications Verification AK104	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .

HY-173124

CDK2/FLT4/PDGFRA-IN-1	CDK VEGFR PDGFR Apoptosis	Cancer
CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC₅₀s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells .

HY-122751

(R)-DNMDP	Phosphodiesterase (PDE)	Cancer
(R)-DNMDP is a potent and selective cancer cell cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, binds PDE3A directly. (R)-DNMDP has a 500-fold lower EC₅₀ compared to the (S)-enantiomer in HeLa cell line .

HY-135008

J14 1 Publications Verification	Reactive Oxygen Species (ROS)	Cancer
J14 is a reversible sulfiredoxin inhibitor with an IC₅₀ of 8.1 μM. J14 induces oxidative stress (intracellular ROS accumulation) by inhibiting sulfiredoxin, leading to cytotoxicity and cancer cell death .

HY-168497

C-MS023	Histone Methyltransferase	Cancer
C-MS023 is a photo-activatable MS023 (HY-19615) prodrug, achieving spatiotemporal inhibition of Histone Arginine Asymmetric Dimethylation. C-MS023 inhibits PRMT6 mediated asymmetric dimethylation of H3 arginine 2 (H3R2me2a), with an estimate IC₅₀ of 0.2224 μM. The photolysis of C-MS023 could be triggered by visible light irradiation at 420 nm, thereby liberating MS023 for effective downregulation of histone arginine asymmetric dimethylation and DNA replication-related transcriptomic activities .

Cat. No.	Product Name	Target	Research Area